IL2 and neoplasm: Although TAB004 alone did not improve survival, since Lip-MSA-IL-2 has been shown to activate macrophage cytotoxicity against cancer cells (83), it is possible that Lip-MSA-IL-2 likely enhances the recruitment and activation of macrophages once TAB004 is bound to tMUC1-expressing tumor cells.